Evaluation of the Variation in Quality of Life During Medical Transition for Transgender People.

NCT ID: NCT05273112

Last Updated: 2023-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-30

Study Completion Date

2030-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transgender people can benefit from psychological, psychiatric, endocrinological support, sexual reassignment surgery, sexology support and dermatological care. The value of transitional care courses is scientifically recognized. Currently, the modalities of decision and realization of the care paths are heterogeneous on the territory, little standardized, and are the subject of debates between representatives of users and medical teams.

The french national report of IGAS from 2011 warns of the need to argue and legitimize care practices through more numerous, more exhaustive scientific studies, presenting a better level of evidence

Since 2011, no prospective study has been carried out on the national and international level, making it possible to assess the relevance of the planned care modalities. This research project, conducted over five consecutive years at the first contact of a transgender people with a care device, aims to correlate a variation in the quality of life of people with the characteristics of the care methods provided. This is a first proposal to assess care practices for transgender people. The results of this study would first allow us to infer the care modalities most suited to the needs of people. Secondly, secondary hypotheses could support new experimental protocols.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research is a prospective multicenter cohort study with a 3-year and 5-year follow-up of transgender people in medical transition.

Main aim:

Evaluate the evolution of the quality of life during five years in transgender people who benefit from transition support cares.

Secondary objectives:

Secondary objective n°1 :

Identify the different factors that influence the evolution of quality of life evaluated over three years in transgender people who benefit from transition support cares.

Secondary objective n°2 :

Evaluate the evolution of the satisfaction of the shared medical decision for transgender people in medical transition.

Secondary objective n°3 :

Evaluate the evolution of the satisfaction of body image for transgender people in medical transition.

Secondary objective n°4 :

Evaluate the evolution of psychiatric comorbidities for transgender people in medical transition.

Secondary objective n°5 :

Evaluate the benefits and limits in long term (five years) on the quality of life, the satisfaction of the shared medical decision, the satisfaction of body image and the evolution of psychiatric comorbidities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gender Dysphoria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* With a diagnosis of Gender Dysphoria according to DSM5 diagnostic criteria
* Wishing to benefit from supportive care for their transition trajectory and addressing a care system represented by the collaborating centers participating in the study,
* Willing to comply with all study procedures and duration,
* Understanding and able to speak French.

Exclusion Criteria

* Minor or adult under curatorship, under judicial protection, persons deprived of their liberty
* Refusal to participate after clear and fair information from the study
* Person with sexual reassignment surgery or with cross hormon therapy since two years.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Lille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François MEDJKANE, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier de Béziers

Béziers, , France

Site Status

CHU de Bordeaux

Bordeaux, , France

Site Status

CHU de Brest

Brest, , France

Site Status

CHU de Caen

Caen, , France

Site Status

CHU de Lille

Lille, , France

Site Status

Maison de Santé Lille Moulins

Lille, , France

Site Status

Maison de Santé Lille Sud

Lille, , France

Site Status

CHU de Lyon

Lyon, , France

Site Status

G..R.E.T.T.I.S

Lyon, , France

Site Status

Hopital de la Conception - Marseille

Marseille, , France

Site Status

CHU de Nice

Nice, , France

Site Status

Centre Hospitalier Maison Blanche

Paris, , France

Site Status

Centre Hospitalier Sainte-Anne

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

François MEDJKANE, MD

Role: CONTACT

0320445962 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cyril IMBERT

Role: primary

Romain WEIGERT

Role: primary

Véronique KERLAN

Role: primary

Yves REZNIK

Role: primary

Francois MEDJKANE

Role: primary

Anne-Laure DEMARTY

Role: backup

Nassir MESSAADI

Role: primary

Sophie DUPONT

Role: primary

Ludovic SOUILLER

Role: primary

Lucie JUREK

Role: backup

Nicolas MOREL-JOURNEL

Role: primary

Delphine DRAI

Role: primary

Michel BENOIT

Role: primary

Jean CHAMBRY

Role: primary

Thierry GALLARDA

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A00154-37

Identifier Type: OTHER

Identifier Source: secondary_id

PREPS-19-0078

Identifier Type: OTHER

Identifier Source: secondary_id

2020_09

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.